{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T02:58:27Z","timestamp":1789441107730,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clinthera.2015.04.015","type":"journal-article","created":{"date-parts":[[2015,6,6]],"date-time":"2015-06-06T04:32:32Z","timestamp":1433565152000},"page":"1483-1492.e1","source":"Crossref","is-referenced-by-count":26,"title":["Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Canagliflozin in Healthy Chinese Subjects"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01707316","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Xia","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Polidori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Stieltjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Sha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sveta","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damayanthi","family":"Devineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2015.04.015_bib1","unstructured":"World Health Organization. Diabetes Fact Sheet No. 312. http:\/\/www.who.int\/mediacentre\/factsheets\/fs312\/en\/. Accessed May 29, 2014."},{"key":"10.1016\/j.clinthera.2015.04.015_bib2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/jdi.12057","article-title":"Changing characteristics of the type 2 diabetes epidemic of China and other Asian countries","volume":"4","author":"Yang","year":"2013","journal-title":"J Diabetes Investig"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2015.04.015_bib3","doi-asserted-by":"crossref","first-page":"S264","DOI":"10.2337\/dc11-s223","article-title":"Therapy in the early stage: incretins","volume":"34","author":"Cernea","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.04.015_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/diaclin.25.4.131","article-title":"Diabetes treatment, part 2: oral agents for glycemic management","volume":"25","author":"Fowler","year":"2007","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.clinthera.2015.04.015_bib5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3810\/hp.2013.04.1020","article-title":"Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial","volume":"41","author":"Bode","year":"2013","journal-title":"Hosp Pract (1995)"},{"key":"10.1016\/j.clinthera.2015.04.015_bib6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.clinthera.2014.02.022","article-title":"Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants","volume":"36","author":"Devineni","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2015.04.015_bib7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.2337\/dc11-1926","article-title":"Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.04.015_bib8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318680-000000000-00000","article-title":"Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus","volume":"70","author":"Neumiller","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2015.04.015_bib9","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.04.015_bib10","unstructured":"Canagliflozin (Invokana\u2122) Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2013. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204042s000lbl.pdf. Accessed on March 5, 2014."},{"key":"10.1016\/j.clinthera.2015.04.015_bib11","unstructured":"European Medicines Agency. Assessment report: Canagliflozen. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002649\/WC500156457.pdf. Accessed on March 29, 2015."},{"key":"10.1016\/j.clinthera.2015.04.015_bib12","series-title":"NSW","year":"2013"},{"key":"10.1016\/j.clinthera.2015.04.015_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2015.04.015_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/j.1463-1326.2011.01406.x","article-title":"Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects","volume":"13","author":"Sha","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.04.015_bib15","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5414\/CP202218","article-title":"Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants","volume":"53","author":"Devineni","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.04.015_bib16","article-title":"Effect of food on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, and assessment of dose proportionality in healthy participants","author":"Devineni","year":"2014","journal-title":"Clinical Pharm in Drug Dev"},{"key":"10.1016\/j.clinthera.2015.04.015_bib17","unstructured":"European Medicines Agency. Invokana\u2122. Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002649\/WC500156456.pdf. Accessed on August 19, 2014."},{"key":"10.1016\/j.clinthera.2015.04.015_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1463-1326.2012.01558.x","article-title":"Canagliflozin improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin","volume":"14","author":"Devineni","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.04.015_bib19","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/clpt.2008.141","article-title":"The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies","volume":"84","author":"Yasuda","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2015.04.015_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40262-013-0084-3","article-title":"Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus","volume":"52","author":"Hoeben","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2015.04.015_bib21","doi-asserted-by":"crossref","first-page":"e110069","DOI":"10.1371\/journal.pone.0105638","article-title":"Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes","volume":"9","author":"Sha","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2015.04.015_bib22","unstructured":"Inagaki N, Kondo K, Iwasaki T, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM). Poster presented at: 71st Scientific Session of the American Diabetes Association (ADA); June 24-28, 2011; San Diego, CA. Abstract # 0999-P."},{"key":"10.1016\/j.clinthera.2015.04.015_bib23","unstructured":"Sakai M, Matsukawa M, Azuma J, et al. A study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of a new SGLT2 inhibitor TA-7284\/Canagliflozin in healthy Japanese subjects. Poster presented at: The 53rd Annual Meeting of the Japan Diabetes Society; May 27-29, 2010; Okayama, Japan."},{"key":"10.1016\/j.clinthera.2015.04.015_bib24","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1472-6823-14-37","article-title":"Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies","volume":"14","author":"Sinclair","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clinthera.2015.04.015_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3810\/pgm.2014.05.2753","article-title":"Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results","volume":"126","author":"Usiskin","year":"2014","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2015.04.015_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12090","article-title":"Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease","volume":"15","author":"Yale","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2015.04.015_bib27","doi-asserted-by":"crossref","first-page":"E867","DOI":"10.1210\/jc.2012-4205","article-title":"Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus","volume":"98","author":"Polidori","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2015.04.015_bib28","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1053\/j.ajkd.2011.02.393","article-title":"GFR estimating equations in a multiethnic Asian population","volume":"58","author":"Teo","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2015.04.015_bib29","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1681\/ASN.2006040368","article-title":"Modified glomerular filtration rate estimation equation for Chinese patients with chronic kidney disease","volume":"17","author":"Ma","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2015.04.015_bib30","doi-asserted-by":"crossref","unstructured":"Devineni D, Manitpisitkul P, Vaccaro N, et al. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants. Int J Clin Pharmacol Ther. 2015;53:41\u201353.","DOI":"10.5414\/CP202157"},{"key":"10.1016\/j.clinthera.2015.04.015_bib31","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2015.04.015_bib32","unstructured":"Ji L, Han P, Liu Y, et al. Canagliflozin in Asian subjects with type 2 diabetes on metformin (MET) alone or in combination with sulphonylurea (SU). Poster presented at: 22nd Biennial World Diabetes Congress of the International Diabetes Federation (IDF); December 2-6, 2013; Melbourne, Australia."},{"key":"10.1016\/j.clinthera.2015.04.015_bib33","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/dom.12385","article-title":"Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea","volume":"17","author":"Ji","year":"2015","journal-title":"Diabetes Obes Metab"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815002842?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291815002842?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T22:54:17Z","timestamp":1537570457000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291815002842"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0149291815002842"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2015.04.015","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}